CDER Launches Inspections Web Page

FDA has launched a new Web page to highlight how the agency uses inspections to help ensure drug safety and quality. “In order to efficiently share relevant information about inspections for human drugs and make it more accessible, FDA is bringing certain data together on a single public Web page,” CDER principal deputy director Jacqueline Corrigan-Curay is quoted in a release as saying. “Along with manufacturers, we have an important role to help ensure drug safety and quality in a transparent way.”

The new page provides an overview of the agency’s work to carefully monitor drug manufacturers' compliance with current good manufacturing practice requirements. It also includes information about FDA’s regulatory tools, such as Warning Letters, and actions following an inspection. Additionally, it links to the agency’s data dashboard page that covers compliance actions.